We were told that Pfizer/BioNTech is a German company. But it is actually a German-Chinese company. Since I first found that Pfizer/BioNTech had an MOU with Fosun Pharmaceuticals, a major CCP-linked pharmaceutical company based in Shanghai, to make the Pfizer/BioNTech MRNA vaccines, I knew that with a bit more digging I would find China at the heart of these acts of war.
BioNTech’s SEC filing shows that the MOU with Fosun Pharmaceuticals includes an equity investment by Fosun in BioNTech. In other words, the CCP is an equity investor in BioNTech: “As part of the strategic alliance with Shanghai Fosun Pharmaceutical (Group) Co., Ltd (“Fosun Pharma”; Stock Symbol: 600196.SH, 02196.HK) whereby the two companies will work together on the development of BNT162 in China, Fosun agreed to make an equity investment which was received in mid-April 2020. The issuance of 1,580,777 ordinary shares with the nominal amount of k€ 1,581 was registered within the commercial register (Handelsregister) as of April 23, 2020.” Not only that but: “Ai-Min Hui, President of Global R&D, and Chief Medical Officer of Fosun Pharma said: ”We are closely working with BioNTech and regulatory authorities to evaluate the safety and efficacy of the vaccine candidate, in order to synchronize the development process in China with other countries, and to bring the vaccine to public as soon as possible, if the vaccine succeeds.” [
https://www.sec.gov/Archives/edgar/data ... d424b3.htm]
Fosun is not separate from the CCP; it is the CCP: Fosun acquired almost half of Sinopharm: “In 2003 Fosun Pharmaceutical acquired 49% stake of Sinopharm Group (Chinese: 国药控股). […] In 2008, a year before the initial public offering of Sinopharm Group, Fosun Pharmaceutical owned the direct parent company of Sinopharm Group, Sinopharm Industrial Investment (Chinese: 国药产业投资) instead; the majority owner of the joint venture was state-owned China National Pharmaceutical Group (Sinopharm).” 2003年年报 [2003 Annual Report] (PDF). Fosun Industrial. 24 April 2004. Retrieved 5 August 2018– via Shanghai Stock Exchange website. [^ 国药集团复星联合成立首家混合所有制药企. 企业观察报 (in Chinese (China)). 4 August 2014. Retrieved 5 August 2018 – via Sina; ^ 2009年年报 [2009 Annual Report] (PDF). Fosun Pharmaceutical. 25 March 2010. Retrieved 5 August 2018 – via Shanghai Stock Exchange website.; ^ "Connection Transaction" (PDF) (Press release). Shanghai: Fosun International. 20 June 2008.]
Sinopharm, of course, as you see above, of which Fosun owns almost half, is owned in turn directly by the Chinese State and thus reports directly to the CCP.
The initial BioNTech/Fosun MOU seems to imply that all of the BioNTech/Fosun joint ventures’ activity is in China, or in regions aligned with or close to China. But is that now the case? Fosun Pharma did not stay in China.
It came here. Fosun Pharmaceuticals is now also Fosun Pharmaceuticals USA, with branches for R and D and product formulation in Boston, MA and Princeton, NJ: [
https://fosunpharmausa.com/covid19/pcr/]
It is producing formulations and products in the US for distribution in the US and around the world. Fosun Pharma has built a “global operation strategy” for the manufacture of COVID-19 vaccines, COVID-19 PCR tests and COVID-19 antigen tests:
“Fosun Pharma has built a strong root in China and developed a global operation strategy, with pharmaceutical manufacturing and R&D being the largest and core business segment, […]”
“In 2021, the revenue from new and sub-new products including COMIRNATY® (mRNA COVID-19 vaccine, also known as BNT162b2), […] accounted for over 25% of the revenue in the pharmaceutical manufacturing segment;
· Revenue from regions outside Mainland China and countries overseas reached RMB13,599 million, accounting for 34.86% of the total revenue, marking a step forward on globalization.” [Italics mine].
And more: “Continuously strengthening the global operation capability and making further enhancement for globalization, Fosun Pharma has formed a global operating system for R&D, manufacturing and commercialization, and continuously expands overseas markets. [..] Globalization capability is continuously strengthened. The second headquarters in the United States help to build a global business landscape with full coverage of R&D, manufacturing and commercialization.[…]
“By the end of 2021, Fosun Pharma’s overseas commercialization team with over 1,200 employees has built marketing platforms in the United States, Africa and Europe [italics mine] and has achieved direct sales of formulations to the U.S. market. […] The COVID-19 test kit by Fosun Diagnostics has been sold in over ten countries. […] Gland Pharma, a holding subsidiary in India, received approvals from the US FDA for 13 generic drugs in 2021.
“Leveraging the current global manufacturing capability and world-class manufacturing facilities [...] Fosun Pharma has accelerated the acquirement of international GMP certification of domestic production lines, laying a solid foundation for exporting domestic products. In January and March 2022, Fosun Pharmaceutical Industrial obtained the Medicines Patent Pool (MPP)’s license to produce and supply the generic version of Merck’s oral COVID-19 treatment Molnupiravir and Pfizer’s oral COVID-19 treatment Nirmatrelvir, as well as the co-packaged product of Nirmatrelvir and Ritonavir of Pfizer [….]. The license includes both ingredients and the finished drug. Through this license, Fosun Pharma devoted itself further to fighting against the pandemic around the world.”
Fosun Pharma USA offers potential partners: “A global reach with a focus on the United States and China markets”. It offers “US Rights” and “Global Rights” as well as “China Rights.” [
https://fosunpharmausa.com/innovative-medicine/]
[
https://fosunpharmausa.com/fosun-pharma ... ouncement/].
The FDA Filing for the Fosun Pharma USA facility says the facility is authorized to “develop specifications,” including for the PCR tests and antigen tests it creates, and that the facility can also have US agents: [
https://fda.report/Company/Fosun-Pharma-Usa-Inc]
This is crucial. Fosun Pharmaceuticals does not just partner with Pfizer/BioNTech to make the COVID-19 vaccines: they make, as noted, the PCR tests that are the one primary metric that determine the scale of the pandemic in North America and Western Europe and thus the “lockdowns” of whole countries, whole industrial sectors.
A CCP-run company, and CCP-created product, thus, decides — who can go to work or school, who must close his or her shop, who can or cannot travel — in all of Europe and the US: [
https://fosunpharmausa.com/covid19/pcr/]. A CCP-run company decides the formulation of the PCR and antigen tests that go deep into the nasopharyngeal cavities of Westerners who are forced, week after week, to test and test and test with these products. This is what is on the Fosun Pharma USA’s product pages: